North East and North Cumbria
ICS Formulary
ICS Formulary
10 Musculoskeletal and joint diseases
10-02-02 Skeletal muscle relaxants
| Baclofen |
|
First Choice
|
|
|
unlicensed) are also approved; 36mg in 12ml, and 72mg in 12ml intrathecal injections.
| Diazepam |
|
First Choice
|
|
 MHRA Drug Safety Update (Jan 2026): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs |
|
|
| Cannabis extract Sativex® |
|
Formulary
|
|
|
NENC Shared Care Protocol: Sativex for the treatment of spasticity in multiple sclerosis NICE NG144: Cannabis-based medicinal products |
|
| Tizanidine |
|
Formulary
|
|
|
Links
- Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities
- MHRA Drug Safety Update (Jan 2026): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs
- NENC Shared Care Protocol: Sativex for the treatment of spasticity in multiple sclerosis
NHS England Urgent Clinical Commissioning Policy Statement (170018/P)- NICE NG144: Cannabis-based medicinal products
- NICE TA1031:Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over
- NICE TA1069: Efgartigimod for treating antibody-positive generalised myasthenia gravis
- NICE TA588: Nusinersen for treating spinal muscular atrophy
- NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
- NICE TA755: Risdiplam for treating spinal muscular atrophy
- NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence